COSMO Pharmaceuticals NV/ NL0011832936 /
2024-07-24 5:12:29 PM | Chg. +0.75 | Volume | Bid5:20:00 PM | Ask5:20:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
69.60CHF | +1.09% | 218 Turnover: 15,172.20 |
-Bid Size: - | -Ask Size: - | 1.13 bill.CHF | - | - |
GlobeNewswire
06-18
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tab...
GlobeNewswire
2020-11-12
RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growt...
GlobeNewswire
2020-08-13
RedHill Biopharma Provides Q2/2020 Financial Results and Operational Highlights
GlobeNewswire
2020-08-13
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing...
GlobeNewswire
2020-04-06
RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy
GlobeNewswire
2020-03-04
RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights
GlobeNewswire
2019-12-17
RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers’ Diarrhea
GlobeNewswire
2019-11-19
RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights